Arsthinol
| Names | |
|---|---|
| Preferred IUPAC name
 N-{2-Hydroxy-5-[4-(hydroxymethyl)-1,3,2-dithiarsolan-2-yl]phenyl}acetamide  | |
| Identifiers | |
3D model (JSmol)  | 
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.003.965 | 
| EC Number | 
  | 
| KEGG | |
PubChem CID  | 
|
| UNII | |
CompTox Dashboard (EPA)  | 
|
  | |
  | |
| Properties | |
| C11H14AsNO3S2 | |
| Molar mass | 347.28 g·mol−1 | 
| Pharmacology | |
| P01AR01 (WHO) QP51AD01 (WHO) | |
| Oral | |
| Pharmacokinetics: | |
| 89 % Hepatic | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). 
Infobox references  | |
Arsthinol (INN) is an organoarsenic compound with the formula HOCH2CHCH2S2AsC6H3(OH)NHCOCH3. A antiprotozoal agent, it was first reported in 1949. It arises by the reaction of acetarsol with 2,3-dimercaptopropanol (British anti-Lewisite) and has been demonstrated to be effective against amoebiasis and yaws. It was marketed a few years later by Endo Products (Balarsen, Tablets, 0.1 g).
Among trivalent organoarsenicals, arsthinol was considered very well tolerated. Recently, it was studied for its anticancer activity.